Immunoreactive T and Tn antigens in malignancy: Role in carcinoma diagnosis, prognosis, and immunotherapy

Transfusion Medicine Reviews

Volumn 14, Issue 4, 2000, Pages 312-325

  Desai, Parimal R ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CANCER VACCINE; THOMSEN ANTIGEN; TN ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CARCINOGENESIS; EARLY DIAGNOSIS; HUMAN; IMMUNOASSAY; PROGNOSIS; REVIEW; VACCINATION;

EID: 0033787621     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tmrv.2000.16229     Document Type: Article

References (122)

1. Blood group MN specific substances and precursors in normal and malignant human breast tissues
2. Blood group MN antigens and precursors in normal and malignant human breast glandular tissue
3. Ein vermehrungsfahiges agens als veranderer des isoagglutinatorischen verhalten der roten blutkorperchen, eine bisher unbekannte quelle der fehlbestimmung
4. Modification of human red cells by virus action. I. The receptor gradient for virus action in human red cells
5. Inactivation of human erythrocyte agglutinogens M and N by influenza viruses and receptor-destroying enzyme
6. Enzymatic and nonenzymatic alterations of erythrocyte surface antigens
7. Untersuchungen uber T-Antigen und T-Agglutinin
8. On the existence, outside human blood, of substances convertible into receptors T
9. Distribution of the T-antigen on erythroid cell surfaces: Studies with peanut agglutinin, an anti-T specific lectin
10. Are pancarcinoma T and Tn differentiation antigens?
11. Anemie hemolytique acquise avec polyagglutinabilite des hematies par un nouveau facteur present dans le serum humain normal [anti-Tn]
12. Tn epitopes, immunoreactive with ordinary anti-Tn antibodies, on normal desialylated human erythrocytes and on Thomsen-Friedenreich antigen isolated therefrom
13. Permanent mixed-field polyagglutinability (PMFP). I. Serological observations
14. Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome
15. Enzymatic synthesis of human blood group M-, N- and T-specific structures
16. Demonstration of T-transferase deficiency in Tn-polyagglutinable blood samples
17. Biosynthesis of blood group T-, N-, and M-specific immunodeterminants on human erythrocyte antigens
18. The M, N, N(vg) receptors of Tn-erythrocytes
19. Erythrocyte membrane modification in malignant diseases of myeloid and lymphoreticular tissue. I. Tn-polyagglutination in acute myelocyte leukemia
20. Tn polyagglutination preceding acute leukemia
21. Common precursors of human blood group MN specificities
22. Synthesis of T [β-D-Gal-(1 → 3)-α-D-GalNAc]-antigenic determinant in a form useful for the preparation of an effective artificial antigen and the corresponding immunoadsorbent
23. Human blood-group MN and precursor specificities: Structural and biological aspects
24. Molecular basis of Tn-polyagglutinability
25. Aspects of human blood group MN and their precursors
26. Synthesis of O-(2-acetamido-2-deoxy-α-D-galactopyranosyl)-N-tosyl-L-serine
27. Acquired hemolytic anemia with polyagglutinability of red blood cells due to a new factor present in normal human serum (anti-Tn)
28. Human carcinoma-associated precursor antigens of the blood group MN system and the host's immune responses to them
29. Origin of anti-Thomsen-Friedenreich (T) and Tn agglutinins in man and in White Leghorn chicks
30. T and Tn general carcinoma autoantigens
31. Exploiting altered glycosylation patterns in cancer: Progress and challenges in diagnosis and therapy
32. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism
33. Blood group-like activity released by human mammary carcinoma cells in culture
34. Expression of a cryptic cell surface antigen in primary cell cultures from human breast cancer
35. Blood group precursor T-antigen expression in human urinary bladder carcinoma
36. Decreased levels of circulating lyric anti-T in the serum of patients with metastatic gastrointestinal cancer: A correlation with disease burden
37. Structure and function of the Ca antigen
38. The polymorphic epithelial mucin as a target for immunotherapy
39. Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA
40. Mucins: Structure, function, and associations with malignancy
41. Cellular mucins: Targets for immunotherapy
42. Mechanisms underlying aberrant glycosylation of MUC 1 mucin in breast cancer cells
43. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine with the VTSA motif of MUC 1 tandem repeats
44. Influence of orally administered antibiotics on anti-T agglutinin of normal subjects and of cirrhotic patients
45. Immunology of cancer
46. Isolation and properties of human blood-group NN and meconium-Vg antigens
47. Blood group MN precursors as human breast carcinoma-associated antigens and 'naturally' occurring human cytotoxins against them
48. Blood group Tn-active macromolecules from human carcinomas and erythrocytes: Characterization of and specific reactivity with mono- and poly-clonal anti-Tn antibodies induced by various immunogens
49. Some physical properties of human NN and Me-Vg blood-group antigens
50. Subunit composition of human blood group MN antigen
51. Pancarcinoma T and Tn epitopes: Autoimmunogens and diagnostic markers that reveal incipient carcinomas and help establish prognosis
52. Breast cancer patient's cell-mediated immune response to Thomsen-Friedenreich (T) antigen
53. Proposed molecular basis of murine tumor cell-hepatocyte interaction
54. Comparison by leukocyte adherence inhibition of human immune response to cancer-associated immunogens, Thomsen-Friedenreich (T) and Tn, myelin basic protein, and organ-specific cancer neoantigens
55. Carcinoma autoantigens T and Tn and their cleavage products interact with Gal/GalNAc-specific receptors on rat Kupffer cells and hepatocytes
56. Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast carcinoma recurrence
57. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma
58. T/Tn pancarcinoma autoantigens: Fundamental, diagnostic, and prognostic aspects
59. T and Tn pancarcinoma markers: Autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy
60. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy
61. Cross-reacting carcinoma-associated antigens with blood group and precursor specificities
62. Tn epitope (N-acetyl-D-galactosamine-α-O-serine/threonine) density in primary breast carcinoma: A functional predictor of aggressiveness
63. T (Thomsen-Friedenreich) and Tn epitope location and their spatial relations to adhesion plaques on human breast carcinoma cells: Immunogold-silver staining studies at scanning electron microscopic level
64. Tn, a carcinoma-associated antigen, reacts with anti-Tn of normal human sera
65. Evaluation and management of high risk and premalignant lesions of the breast
66. Quantitative computerized image analysis of Tn and T (Thomsen-Friedenreich) epitopes in prognostication of human breast carcinoma
67. Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells
68. High expression rate of Tn antigen in metastatic lesions of uterine cervical cancers
69. Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody: A possible marker of recurrence
70. Blood group antigens and ploidy as prognostic factors in urinary bladder carcinoma
71. Detection of Tn antigen with Vicia villosa agglutinin in urinary bladder cancer: Its relevance to the patient's clinical course
72. T-antigen: A prognostic indicator of high recurrence index in transitional carcinoma of the bladder
73. Thomsen-Friedenreich antigen in bladder cancer tissues detected by monoclonal antibody
74. Flow cytometric evaluation of Thomsen-Friedenreich antigen on transitional cell cancer using monoclonal antibody
75. Nuclear volume and expression of T-antigen, sialosyl-Tn-antigen, and Tn-antigen in carcinoma of the human bladder
76. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas: A reevaluation
77. Expression of PNA-binding sites on specific glycoproteins by human melanoma cells is associated with high metastatic potential
78. An antitumor antibody in normal human serum: Reaction of anti-T with breast carcinoma cells
79. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2 → 6 α-N-acetylgalactosaminyl (sialosyl-Tn) epitope
80. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: Serous and mucinous tumors exhibit distinctive patterns of expression
81. Structural studies of sialylated oligosaccharides of human midcycle cervical mucin
82. Oligosaccharide structures of isolated human colonic mucin species
83. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer
84. Expression of Tn, sialosyl Tn, and T antigens in human pancreas
85. Simple mucin-type Tn and sialosyl-Tn carbohydrate antigens in salivary gland carcinomas
86. Identification of Thomsen's antigen in leukocytes of leukemic patients
87. Detection of the Tn antigen in leukemia using monoclonal anti-Tn antibody and immunohistochemistry
88. Flow cytometric analysis of T and Tn epitopes on chronic lymphocytic leukemia cells
89. Decrease in naturally occurring serum anti-Tn antibodies correlates positively with the expression of Tn epitope on the surface of B-cell chronic lymphocytic leukemia cells
90. The fundamental and diagnostic role of T and Tn antigens in breast carcinoma at the earliest histologic stage and throughout
91. Patients' immune response to breast and lung carcinoma-associated Thomsen-Friedenreich (T) specificity
92. Delayed-type cutaneous hypersensitivity to Thomsen-Friedenreich (T) antigen in patients with pancreatic cancer
93. Immune reactivity to Thomsen-Friedenreich antigen in patients with lung cancer detected by superoxide assay-leukocyte adherence inhibition test
94. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes
95. T cell recognition of Tn-glycosylated peptide antigens
96. Carbohydrate and peptide specificity of MHC Class II-restricted T cell hybridomas raised against an O-glycosylated self peptide
97. T-cell recognition of tumor-associated carbohydrates: The nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity
98. The distribution of 'T' agglutinins in human sera
99. Automatic determination of anti-T antibodies in patients with breast carcinoma and controls
100. Anti-T antibody in malignant melanoma patients
101. Heterophile antibodies, immunoglobulin levels, and the evaluation of anti-T activity in cancer patients and controls
102. Antibody responses to T-activated red cells in children from high- and low-risk areas of cancer of the oesophagus in Transkei
103. Relation of human blood groups MN to cancer cell surface antigens and to receptors for oncogenic viruses
104. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model
105. Detection of lung- and breast-carcinoma by quantitating serum anti-T IgM levels with a sensitive, solid-phase immunoassay
106. Carcinoma detection by quantitation and interrelation of serum anti-T IgM and total IgM
107. Anti-Thomsen-Friedenreich (T) antibody-based ELISA and its application to human breast carcinoma detection
108. Antibodies to pancarcinoma Tn epitope: Their altered levels in breast carcinoma patients
109. Depression of anti-T IgM antibody levels in human carcinoma (CA) detection and their alterations in breast CA patients vaccinated with T antigen
110. Immunologic response of cancer patients modified by immunization with tumor vaccine
111. Studies on the immunogenicity of synthetic and natural Thomsen-Friedenreich (TF) antigens in mice: Augmentation of the response by quil A and SAF-m adjuvants and analysis of the specificity of the responses
112. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen
113. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus detox adjuvant
114. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinea-CEA vaccine
115. Active specific immunotherapy of melanoma
116. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine
117. Uncovered Galβ-3GalNAc-α-O-Ser/Thr (T) and its immediate precursor epitope Tn are pivotal in carcinoma (CA) pathogenesis, diagnosis and prognosis. Human T (Tn) antigen is effective as CA vaccine
118. Survival from breast cancer according to tumor size and nodal status